Our Company

biOasis Technologies Inc. (TSX-V:BTI) is a publically traded biopharmaceutical company focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system ("CNS") diseases and disorders. Of particular interest is the creation of therapeutic options for patient management to address the limitations to biodistribution presented by the properties of the blood-brain barrier ("BBB"). 

Our Business Strategy
BTI's business strategy emphasizes out-licensing its technologies to qualified partners, and strategic acquisitions of products and technologies relevant to the diagnosis and management of CNS diseases and disorders.

For more about our current development programs click here...


TRANSCEND is a protein Vector that shuttles existing therapeutic drugs across the Blood-Brain Barrier. In November 2010 Bioasis sponsored a research agreement with the National Research Council of Canada to evaluate the ability of biOasis' compounds to cross the blood-brain barrier using real time-domain in vivo optical imaging.

Media & Research

October 7, 2014
biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
October 7th, 2014 – BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF; TSX.V:BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier ("BBB"), engages Willow Tree Capital Group of Toronto, Canada. Willow Tree's full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies worldwide. With its broad transactional experience, Willow Tree specializes in Licensing, strategic consultation and Mergers & Acquisitions services, employing industry-recognized valuation models for life science market value assessments.